Cue Biopharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Cue Biopharma hat ein Gesamteigenkapital von $30.0M und eine Gesamtverschuldung von $7.2M, was einen Verschuldungsgrad von 24% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $54.0M bzw. $23.9M.

Wichtige Informationen

24.0%

Verhältnis von Schulden zu Eigenkapital

US$7.21m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$41.03m
Eigenkapital	US$30.04m
Gesamtverbindlichkeiten	US$23.91m
Gesamtvermögen	US$53.95m

Jüngste Berichte zur Finanzlage

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Nov 04

Recent updates

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Apr 16

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Dec 30

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Aug 11

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Oct 04

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Aug 26

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Aug 10

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

May 18

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12

Cue Biopharma: A First Assessment

May 11

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 19

Cue Biopharma: Too Long To Arrive At Topline Trial Data

Feb 23

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Nov 04

Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer

Jun 10

Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth

Jun 07

Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients

May 10

How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?

Mar 21

We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate

Feb 22

Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?

Jan 27

Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022

Jan 07

Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year

Dec 25

Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)

Nov 29

We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate

Nov 24

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: CUEDie kurzfristigen Aktiva des Unternehmens ($44.7M) übersteigen seine kurzfristigen Passiva ($18.1M).

Langfristige Verbindlichkeiten: CUEDie kurzfristigen Vermögenswerte des Unternehmens ($44.7M) übersteigen seine langfristigen Verbindlichkeiten ($5.8M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: CUE über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: CUEDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 24% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: CUE auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: CUE verfügt über eine ausreichende Liquiditätsreserve für 1 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 9.6% pro Jahr abnimmt.

Cue Biopharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Recent updates

Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma, Inc., Annual General Meeting, Jun 05, 2024

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 20%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Consensus revenue estimates decrease by 25%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

New minor risk - Share price stability

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?

Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma, Inc. Presents Positive Data Update from Ongoing Phase 1 Trials of Cue-101 for Recurrent/Metastatichpv+ Head and Neck Squamous Cell Carcinoma At the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates decrease by 91%, EPS upgraded

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $17.6 million.

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates fall by 24%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board

Cue Biopharma, Inc. Announces Executive Changes

Consensus forecasts updated

Cue Biopharma, Inc. announced that it expects to receive $29.999992 million in funding

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cue Biopharma, Inc. Presents New Positive Data from Ongoing Phase 1 Trial of Cue-101 in Combination with Keytruda for Recurrent/Metastatic Hpv+ Head and Neck Cancer At the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Cue Biopharma Grants FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Consensus revenue estimates fall by 50%

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - Expressing Cancers

Consensus revenue estimates increase by 54%

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cue Biopharma, Inc. Announces Resignation of Cameron Gray as Member of the Board of Directors and All Committees

Insider recently bought US$105k worth of stock

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

Consensus revenue estimates fall by 23%

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

U.S. Food and Drug Administration Accepts Cue Biopharma, Inc Investigational New Drug Application

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Cue Biopharma: A First Assessment

Cue Biopharma, Inc., Annual General Meeting, Jun 09, 2022

Price target decreased to US$24.83

CEO & Director exercised options and sold US$157k worth of stock

Consensus forecasts updated

Price target decreased to US$26.29

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cue Biopharma: Too Long To Arrive At Topline Trial Data

President & Chief Scientific Officer exercised options and sold US$173k worth of stock

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.34 loss in 3Q 2020)

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

CEO & Director exercised options and sold US$462k worth of stock

Cue Biopharma, Inc. Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

President & Chief Scientific Officer exercised options and sold US$176k worth of stock

CEO & Director recently bought US$50k worth of stock

Cue Biopharma, Inc Grants U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

Consensus revenue estimates increase to US$10.4m

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.38 loss in 2Q 2020)

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer

Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth